PD-L2 Is Constitutively Expressed in Normal and Malignant Urothelium

PD-L2 Is Constitutively Expressed in Normal and Malignant Urothelium

The use of immune checkpoint blockade, in particular PD-1 and PD-L1 inhibitors, is now commonplace in many clinical settings including the treatment of muscle-invasive bladder cancer (MIBC). Notwithstanding, little information exists regarding the expression of the alternative PD-1 ligand, PD-L2 in...

Full description

Bibliographic Details
Main Authors: Alexander C. Dowell, Haydn Munford, Anshita Goel, Naheema S. Gordon, Nicholas D. James, K. K. Cheng, Maurice P. Zeegers, Douglas G. Ward, Richard T. Bryan
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Oncology
Subjects:
bladder cancer
immune checkpoint inhibitors
PD-L1 (B7-H1 CD274)
PD-L2: programmed cell death ligand 2
normal urothelium
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.626748/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.626748/full

Similar Items